Nivolumab (Opdivo)

Type: drug

Status: FDA Approved (for recurrent/metastatic HNC, including NPC)

Developer: Bristol-Myers Squibb

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026